Atovaquon

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Half-life
This section has been translated automatically.

> 50 h

Indication
This section has been translated automatically.

Pneumocystis carinii pneumonia or toxoplasmosis in AIDS patients(replacement preparation especially for glucose-6-phosphate dehydrogenase deficiency).

Dosage and method of use
This section has been translated automatically.

3 times 750 mg/day p.o. during meals.

Undesirable effects
This section has been translated automatically.

Nausea, diarrhoea, allergic reactions, headaches, vomiting, insomnia, increase in transaminases and amylases, anemia.

Interactions
This section has been translated automatically.

See Table 1.

Contraindication
This section has been translated automatically.

Pregnancy, nursing.

Preparations
This section has been translated automatically.

Wellvone

Tables
This section has been translated automatically.

Essential interactions of Atovaquon

Aciclovir

Atovaquon plasma mirror ↓

Benzodiazepines

Atovaquon plasma mirror ↓

Cephalosporins

Atovaquon plasma mirror ↓

Fluconazole

Atovaquon plasma mirror ↓

Metoclopramide

Atovaquon plasma mirror ↓

Opiates

Atovaquon plasma mirror ↓

Paracetamol

Atovaquon plasma mirror ↓

Prednisolone

Atovaquon plasma mirror ↑

Rifampicin

Atovaquon plasma mirror ↓ by 50% ↓

Zidovudine (AZT)

Atovaquon ↑ Plasma level by 35%

Outgoing links (2)

Aids; Antiprotozoal agents;

Authors

Last updated on: 29.10.2020